Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Humira adalimumab regulatory update

Eisai disclosed in its fiscal 1Q13 earnings that Humira adalimumab was approved in Japan

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE